Cambridge Oncometrix Company

Cambridge Oncometrix aims to save lives by enabling the early detection of prostate cancer. A condition that is likely to affect 1 in 8 men at some stage of their lives. Cambridge Oncometrix is developing a non-invasive test that will allow men to check the health of their prostate regularly. A simplified version of the test will be available for home use. A more advanced version will be used in medical institutions. This test will be capable of accurately detecting aggressive forms of prostate cancer at the early stages of its development.
Technology: Scientifically-Validated Lifestyle Recommendation
Industry: Personalized Medicine
Headquarters: Haverhill, Suffolk, United Kingdom
Founded Date: 2012
Employees Number: 1-10
Funding Status: Seed

Visit Website
office@camonx.com
@COncometrix
Register and Claim Ownership